Effectiveness of Unified Protocol for Transdiagnostic Treatment in patients with temporomandibular disorders.

Effectiveness of Unified Protocol for Transdiagnostic Treatment on Emotional symptom, Emotion regulation, Kinesiophobia, Pain intensity, Quality of life in patients with temporomandibular disorders.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221021056259N1

Enrollment

Registered

2025-03-08

Start date

2023-09-20

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Temporomandibular Syndrome. Temporomandibular joint disorders

Interventions

Intervention 1: "Participants will be asked to continue their medical treatment as before. Then, the transdiagnostic therapy will be administered to the experimental group in eight 50-minute sessions,

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with temporomandibular syndrome whose disease has been Diagnosed based on DC/TMD criteria.

Exclusion criteria

Exclusion criteria: Age younger than 18 and older than 50 Degree less than middle School degree

Design outcomes

Primary

Measure	Time frame
Emotion Regulation score in DERS-16 questionnaire. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Difficulties in Emotion Regulation Scale (DERS-16).;Anxiety score in DASS-21 questionnaire. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Depression- Anxiety- Stress Scale (DASS-21).;Depression score in DASS-21 questionnaire. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Depression- Anxiety- Stress Scale (DASS-21).;Stress score in DASS-21 questionnaire. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Depression- Anxiety- Stress Scale (DASS-21).	—

Measure

Time frame

Emotion Regulation score in DERS-16 questionnaire. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Difficulties in Emotion Regulation Scale (DERS-16).;Anxiety score in DASS-21 questionnaire. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Depression- Anxiety- Stress Scale (DASS-21).;Depression score in DASS-21 questionnaire. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Depression- Anxiety- Stress Scale (DASS-21).;Stress score in DASS-21 questionnaire. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Depression- Anxiety- Stress Scale (DASS-21).

—

Secondary

Measure	Time frame
Tampa Scale for Kinesiophobia-TSK. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Tampa Scale for Kinesiophobia questionnaire-TSK.;Intensity of pain. Timepoint: Before the intervention and three months after the intervention. Method of measurement: McGill pain questionnaire.;Oral Health Related Quality of Life score in OHIP-14 questionnaire. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Oral Health Impact Profile OHIP-14 questionnaire.	—

Measure

Time frame

Tampa Scale for Kinesiophobia-TSK. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Tampa Scale for Kinesiophobia questionnaire-TSK.;Intensity of pain. Timepoint: Before the intervention and three months after the intervention. Method of measurement: McGill pain questionnaire.;Oral Health Related Quality of Life score in OHIP-14 questionnaire. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Oral Health Impact Profile OHIP-14 questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Molaei

Kashan University of Medical Sciences

fatemeh.molaei@ut.ac.ir+98 21 6635 8962

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026